<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02512575</url>
  </required_header>
  <id_info>
    <org_study_id>D6470C00001</org_study_id>
    <secondary_id>2015-002002-37</secondary_id>
    <nct_id>NCT02512575</nct_id>
  </id_info>
  <brief_title>A Single Ascending Dose Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AZD9567.</brief_title>
  <official_title>A Phase I, Randomized, Single-Blind, Placebo-Controlled Study To Assess The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single Ascending Oral Doses Of AZD9567 In Healthy Subjects.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase I, first-in-human (FIH), randomized, single-blind, placebo-controlled, single
      ascending dose sequential group study in healthy male subjects. The objectives are to study
      the safety, tolerability, pharmacokinetics and effects on glucose homeostasis
      (pharmacodynamics) of AZD9567, an oral differentiated non-steroidal selective glucocorticoid
      receptor modulator (SGRM). The study will also assess the safety, tolerability,
      pharmacokinetics (PK) and pharmacodynamics (PD) of prednisolone 60 mg in comparison with high
      doses of AZD9567 and placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, first-in-human (FIH), randomized, single-blind, placebo-controlled, single
      ascending dose sequential group study in healthy male subjects. The objectives are to study
      the safety, tolerability, pharmacokinetics and effects on glucose homeostasis
      (pharmacodynamics) of AZD9567. Additional exploratory variables (Inflammation biomarkers, ECG
      modelling and taste assessment) will also be evaluated. The study will also assess the
      safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of prednisolone 60 mg
      in comparison with high doses of AZD9567 and placebo. The study will be conducted at a single
      study centre with a planned number of subjects of up to 72 healthy males, aged 18 to 55
      years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 18, 2015</start_date>
  <completion_date type="Actual">September 26, 2016</completion_date>
  <primary_completion_date type="Actual">September 26, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events</measure>
    <time_frame>At screening, Day -2, Day -1, Day 1 (at pre-dose; 3 &amp; 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 and follow-up (7 to 10 days post-dose)</time_frame>
    <description>Safety and tolerability variables included AEs, vital signs (blood pressure and pulse), ECGs (12-lead ECGs, safety ECGs and telemetry), clinical laboratory safety evaluations (haematology, clinical chemistry [including osteocalcin], coagulation, urinalysis [including 24 hour urine cortisol per day {tU-cortisol}]) and physical examinations.
Note: No clinically relevant findings were noted in clinical laboratory results and vial signs assessments. Hence, none of the laboratory or vital signs findings were reported as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Observed Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
    <description>To assess the Cmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. Cmax was taken directly from the individual concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Time to Reach Maximum Plasma Concentration(Tmax)</measure>
    <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
    <description>To assess the tmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. tmax was taken directly from the individual concentration-time curve.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Terminal Half-life (t½λz)</measure>
    <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
    <description>To assess t½λz of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. t½λz was estimated as (ln2)/λz.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC(0-last))</measure>
    <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
    <description>To assess AUC(0-last) of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC)</measure>
    <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
    <description>To assess AUC of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. AUC was estimated by AUC(0-last) + Clast/λz. Clast - the last observed quantifiable concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary Outcome: Relative Change From Baseline of AUC0-4h for Plasma Glucose to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</measure>
    <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
    <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of plasma glucose. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT plasma glucose total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline of AUC0-4h for Serum Insulin to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</measure>
    <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
    <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum insulin. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum insulin total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Change From Baseline of AUC0-4h for Serum C-peptide to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</measure>
    <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
    <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum C-peptide. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum C-peptide total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Pharmacokinetics</condition>
  <condition>Pharmacodynamics</condition>
  <condition>Healthy Subjects</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>AZD9567 oral suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In Part A: up to 8 cohorts with single ascending doses (starting at 2 mg up to 155 mg).
In Part B: one cohort with a single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects randomized to placebo in the first 8 cohorts will receive the same dose volume of oral suspension as subjects on AZD9567 and subjects randomized to placebo in cohort 9(prednisolone cohort) will receive the same number of capsules as subjects on prednisolone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone capsules</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within each cohort 6 subjects will be randomized to receive prednisolone 60mg oral capsules and 2 subjects randomized to receive matching placebo in a fasted state.
Sentinel dosing will not be employed for the prednisolone cohort. The SRC will not be required to evaluate the prednisolone cohort. This cohort can be performed at any time during clinical execution of the study provided the protocol amendment was approved.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9567 Monohydrat</intervention_name>
    <description>AZD9567 oral suspension 0.5 to 10 mg/ml</description>
    <arm_group_label>AZD9567 oral suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral suspension/ Placebo capsule</intervention_name>
    <description>Matching placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone</intervention_name>
    <description>Prednisolone 60mg oral capsules (12 capsules of 5 mg each).</description>
    <arm_group_label>Prednisolone capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures.

          -  Healthy male subjects aged 18 to 55 years with suitable veins for cannulation or
             repeated venipuncture.

          -  Have a body mass index (BMI) between 18 and 29.9 kg/m2 inclusive and weigh at least 50
             kg and no more than 100 kg inclusive.

          -  Normal OGTT at screening (&lt;7.8 mmol/L).

          -  Serum cortisol levels within normal limits at screening (collected as part of the
             clinical chemistry panel).

          -  Able to understand, read and speak the German language.

        Exclusion Criteria:

          -  History of any clinically important disease or disorder which, in the opinion of the
             Investigator, may either put the subject at risk because of participation in the
             study, or influence the results or the subject's ability to participate in the study.

          -  History or presence of gastrointestinal (GI), hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs.

          -  History of or active or latent tuberculosis (TB), or at risk for having acquired TB
             (social workers or prison staff in countries with endemic rates of TB, having lived
             with patients with known TB).

          -  History suggesting abnormal immune function, as judged by the investigator.

          -  Any contraindications to be treated with prednisolone (allergy to any ingredient,
             systemic fungal infection, certain type of malaria, inflammation of the optic nerve,
             or herpes infection of the eye, scheduled to have a live or attenuated live
             vaccination or taking mifepristone).

          -  History of severe affective disorder including depressive or manic-depressive illness
             them self or first degree relatives.

          -  History of previous steroid psychosis

          -  Any clinically important illness, medical/surgical procedure, or trauma within 4 weeks
             of the first administration of IMP.

          -  Any latent or chronic infections (e.g., recurrent sinusitis, genital or ocular herpes,
             urinary tract infection) or at risk of infection (surgery, trauma, or significant
             infection), or history of skin abscesses within 90 days prior to the first
             administration of IMP.

          -  Any clinically important laboratory abnormalities (clinical chemistry, hematology,
             coagulation or urinalysis results), as judged by the investigator. In particular a
             subject with an abnormal value in alkaline phosphatase (ALP), alanine aminotransferase
             (ALT), aspartate aminotransferase (AST), gamma-glutamyl transpeptidase (GGT),
             creatinine, thyroid-stimulating hormone (TSH), fasting glucose, International
             Normalised Ratio (INR), haemoglobin (Hb), white blood cell (WBC), absolute neutrophil
             or platelet count will be excluded.

          -  Any positive result on screening for serum hepatitis B surface antigen (HBsAg),
             hepatitis C antibody and human immunodeficiency virus (HIV).

          -  Abnormal vital signs, after 10 minutes supine rest, defined as any of the following:
             Systolic BP (SBP) &lt; 90mmHg or ≥ 140 mmHg, Diastolic BP (DBP) &lt; 50mmHg or ≥ 90 mmHg,
             Pulse &lt; 45 or &gt; 85 beats per minute (bpm).

          -  Any clinically important abnormalities in rhythm, conduction or morphology of the
             resting ECG and any clinically important abnormalities in the 12-lead ECG, as
             considered by the investigator that may interfere with the interpretation of QTc
             interval changes, including abnormal ST-T-wave morphology, particularly in the
             protocol defined primary lead or left ventricular hypertrophy.

          -  Prolonged QTcF &gt; 450 ms or family history of long QT syndrome.

          -  PR(PQ) interval shortening &lt; 120 ms (PR &gt; 110 ms but &lt; 120 ms is acceptable if there
             is no evidence of ventricular pre-excitation).

          -  PR (PQ) interval prolongation (&gt; 240 ms) intermittent second (Wenckebach block while
             asleep is not exclusive) or third degree AV block, or AV dissociation
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainhard Fuhr, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>PAREXEL International GmbH, Berlin</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 31, 2015</study_first_posted>
  <results_first_submitted>September 22, 2017</results_first_submitted>
  <results_first_submitted_qc>September 27, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 4, 2018</results_first_posted>
  <last_update_submitted>September 27, 2018</last_update_submitted>
  <last_update_submitted_qc>September 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AZD9567</keyword>
  <keyword>Healthy subjects</keyword>
  <keyword>Phase 1</keyword>
  <keyword>placebo controlled</keyword>
  <keyword>single ascending dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Phase 1, single-center (Berlin), randomized, single-blind, placebo-controlled study carried on 72 healthy male participants (8 subjects per cohort). In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2). Participants received treatment in a fasted state</recruitment_details>
      <pre_assignment_details>Screening period (Day -28 to Day -3). For Cohort 7, screening period was up to 21 days</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD9567 - 2 mg</title>
          <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P2">
          <title>AZD9567 - 10 mg</title>
          <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P3">
          <title>AZD9567 - 20 mg</title>
          <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P4">
          <title>AZD9567 - 40 mg</title>
          <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P5">
          <title>AZD9567 - 80 mg</title>
          <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P6">
          <title>AZD9567 - 100 mg</title>
          <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P7">
          <title>AZD9567 - 125 mg</title>
          <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P8">
          <title>AZD9567 - 155 mg</title>
          <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="P9">
          <title>Prednisolone - 60 mg</title>
          <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
        </group>
        <group group_id="P10">
          <title>Pooled Placebo</title>
          <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD9567 - 2 mg</title>
          <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B2">
          <title>AZD9567 - 10 mg</title>
          <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B3">
          <title>AZD9567 - 20 mg</title>
          <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B4">
          <title>AZD9567 - 40 mg</title>
          <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B5">
          <title>AZD9567 - 80 mg</title>
          <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B6">
          <title>AZD9567 - 100 mg</title>
          <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B7">
          <title>AZD9567 - 125 mg</title>
          <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B8">
          <title>AZD9567 - 155 mg</title>
          <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="B9">
          <title>Prednisolone - 60 mg</title>
          <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
        </group>
        <group group_id="B10">
          <title>Pooled Placebo</title>
          <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="6"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="18"/>
            <count group_id="B11" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Cohort 1-8 AZD9567</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44" spread="10"/>
                    <measurement group_id="B2" value="35" spread="14"/>
                    <measurement group_id="B3" value="35" spread="8"/>
                    <measurement group_id="B4" value="35" spread="9"/>
                    <measurement group_id="B5" value="38" spread="12"/>
                    <measurement group_id="B6" value="34" spread="9"/>
                    <measurement group_id="B7" value="41" spread="8"/>
                    <measurement group_id="B8" value="32" spread="8"/>
                    <measurement group_id="B9" value="0" spread="0"/>
                    <measurement group_id="B10" value="0" spread="0"/>
                    <measurement group_id="B11" value="37" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cohort 9 Prenisolone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="0" spread="0"/>
                    <measurement group_id="B6" value="0" spread="0"/>
                    <measurement group_id="B7" value="0" spread="0"/>
                    <measurement group_id="B8" value="0" spread="0"/>
                    <measurement group_id="B9" value="36" spread="9"/>
                    <measurement group_id="B10" value="0" spread="0"/>
                    <measurement group_id="B11" value="36" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pooled Placebo</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                    <measurement group_id="B5" value="0" spread="0"/>
                    <measurement group_id="B6" value="0" spread="0"/>
                    <measurement group_id="B7" value="0" spread="0"/>
                    <measurement group_id="B8" value="0" spread="0"/>
                    <measurement group_id="B9" value="0" spread="0"/>
                    <measurement group_id="B10" value="37" spread="11"/>
                    <measurement group_id="B11" value="37" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events</title>
        <description>Safety and tolerability variables included AEs, vital signs (blood pressure and pulse), ECGs (12-lead ECGs, safety ECGs and telemetry), clinical laboratory safety evaluations (haematology, clinical chemistry [including osteocalcin], coagulation, urinalysis [including 24 hour urine cortisol per day {tU-cortisol}]) and physical examinations.
Note: No clinically relevant findings were noted in clinical laboratory results and vial signs assessments. Hence, none of the laboratory or vital signs findings were reported as AEs.</description>
        <time_frame>At screening, Day -2, Day -1, Day 1 (at pre-dose; 3 &amp; 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 and follow-up (7 to 10 days post-dose)</time_frame>
        <population>All participants who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study. IMP includes AZD9567, Prednisolone 60 mg and placebo.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O9">
            <title>Prednisolone - 60 mg</title>
            <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
          </group>
          <group group_id="O10">
            <title>Pooled Placebo</title>
            <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of AZD9567 by Assessing the Number of Participants With Adverse Events</title>
          <description>Safety and tolerability variables included AEs, vital signs (blood pressure and pulse), ECGs (12-lead ECGs, safety ECGs and telemetry), clinical laboratory safety evaluations (haematology, clinical chemistry [including osteocalcin], coagulation, urinalysis [including 24 hour urine cortisol per day {tU-cortisol}]) and physical examinations.
Note: No clinically relevant findings were noted in clinical laboratory results and vial signs assessments. Hence, none of the laboratory or vital signs findings were reported as AEs.</description>
          <population>All participants who received at least one dose of IMP and for whom any safety post-dose data were available were included in the safety analysis for the study. IMP includes AZD9567, Prednisolone 60 mg and placebo.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE (including events with outcome =death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any serious adverse event (SAE) (including death)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE leading to discontinuation of AZD9567</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Observed Maximum Plasma Concentration (Cmax)</title>
        <description>To assess the Cmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. Cmax was taken directly from the individual concentration-time curve.</description>
        <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
        <population>The pharmacokinetic (PK) analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Observed Maximum Plasma Concentration (Cmax)</title>
          <description>To assess the Cmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. Cmax was taken directly from the individual concentration-time curve.</description>
          <population>The pharmacokinetic (PK) analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
          <units>nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184.9" spread="20.18"/>
                    <measurement group_id="O2" value="751.6" spread="25.03"/>
                    <measurement group_id="O3" value="1327" spread="17.28"/>
                    <measurement group_id="O4" value="2536" spread="38.33"/>
                    <measurement group_id="O5" value="4261" spread="13.88"/>
                    <measurement group_id="O6" value="5835" spread="14.14"/>
                    <measurement group_id="O7" value="6080" spread="21.30"/>
                    <measurement group_id="O8" value="6900" spread="33.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.847</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0238</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.807</ci_lower_limit>
            <ci_upper_limit>0.887</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Time to Reach Maximum Plasma Concentration(Tmax)</title>
        <description>To assess the tmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. tmax was taken directly from the individual concentration-time curve.</description>
        <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Time to Reach Maximum Plasma Concentration(Tmax)</title>
          <description>To assess the tmax of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. tmax was taken directly from the individual concentration-time curve.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="20.18" lower_limit="0.48" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.75" spread="25.03" lower_limit="0.27" upper_limit="1.00"/>
                    <measurement group_id="O3" value="0.51" spread="17.28" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O4" value="0.75" spread="38.33" lower_limit="0.50" upper_limit="1.00"/>
                    <measurement group_id="O5" value="1.00" spread="13.88" lower_limit="1.00" upper_limit="1.50"/>
                    <measurement group_id="O6" value="1.00" spread="14.14" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O7" value="1.00" spread="21.30" lower_limit="0.50" upper_limit="1.50"/>
                    <measurement group_id="O8" value="1.25" spread="33.97" lower_limit="0.58" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Terminal Half-life (t½λz)</title>
        <description>To assess t½λz of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. t½λz was estimated as (ln2)/λz.</description>
        <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Terminal Half-life (t½λz)</title>
          <description>To assess t½λz of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. t½λz was estimated as (ln2)/λz.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.716" spread="0.8182" lower_limit="3.46" upper_limit="5.89"/>
                    <measurement group_id="O2" value="5.444" spread="2.157" lower_limit="2.70" upper_limit="9.22"/>
                    <measurement group_id="O3" value="3.929" spread="1.237" lower_limit="3.13" upper_limit="6.31"/>
                    <measurement group_id="O4" value="4.199" spread="1.417" lower_limit="2.28" upper_limit="6.13"/>
                    <measurement group_id="O5" value="5.286" spread="1.469" lower_limit="3.50" upper_limit="6.97"/>
                    <measurement group_id="O6" value="5.297" spread="1.041" lower_limit="3.89" upper_limit="7.02"/>
                    <measurement group_id="O7" value="4.664" spread="1.052" lower_limit="3.49" upper_limit="6.16"/>
                    <measurement group_id="O8" value="6.449" spread="1.778" lower_limit="4.64" upper_limit="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC(0-last))</title>
        <description>To assess AUC(0-last) of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state.</description>
        <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero to the Time of Last Quantifiable Analyte Concentration (AUC(0-last))</title>
          <description>To assess AUC(0-last) of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="940.6" spread="40.32" lower_limit="3.46" upper_limit="5.89"/>
                    <measurement group_id="O2" value="5069" spread="41.83" lower_limit="2.70" upper_limit="9.22"/>
                    <measurement group_id="O3" value="7598" spread="28.12" lower_limit="3.13" upper_limit="6.31"/>
                    <measurement group_id="O4" value="13860" spread="62.81" lower_limit="2.28" upper_limit="6.13"/>
                    <measurement group_id="O5" value="31600" spread="34.57" lower_limit="3.50" upper_limit="6.97"/>
                    <measurement group_id="O6" value="41850" spread="27.82" lower_limit="3.89" upper_limit="7.02"/>
                    <measurement group_id="O7" value="40930" spread="14.32" lower_limit="3.49" upper_limit="6.16"/>
                    <measurement group_id="O8" value="56940" spread="36.80" lower_limit="4.64" upper_limit="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.930</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0364</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.869</ci_lower_limit>
            <ci_upper_limit>0.991</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC)</title>
        <description>To assess AUC of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. AUC was estimated by AUC(0-last) + Clast/λz. Clast - the last observed quantifiable concentration.</description>
        <time_frame>On Day 1 (at pre-dose and at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12 and 16 hours post-dose), Day 2 (24 hours post-dose) and Day 3 (48 hours post-dose)</time_frame>
        <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
        </group_list>
        <measure>
          <title>Rate and Extent of Absorption of Single Ascending Doses of AZD9567 by Assessment of Area Under the Plasma Concentration-curve From Time Zero Extrapolated to Infinity (AUC)</title>
          <description>To assess AUC of AZD9567 oral suspension following 8 single ascending doses (2, 10, 20, 40, 80, 100, 125 and 155 mg) in Cohorts 1 to 8 in the fasted state. AUC was estimated by AUC(0-last) + Clast/λz. Clast - the last observed quantifiable concentration.</description>
          <population>The PK analysis set consisted of all participants in the safety analysis set who received a dose of AZD9567 and had at least one of the parameters Cmax, AUC / AUC(0-last) evaluable. All protocol deviations were considered for the severity/impact and were accounted when participants were assigned to the PK analysis sets.</population>
          <units>h*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1007" spread="38.22" lower_limit="3.46" upper_limit="5.89"/>
                    <measurement group_id="O2" value="5266" spread="42.57" lower_limit="2.70" upper_limit="9.22"/>
                    <measurement group_id="O3" value="7670" spread="28.26" lower_limit="3.13" upper_limit="6.31"/>
                    <measurement group_id="O4" value="14000" spread="62.53" lower_limit="2.28" upper_limit="6.13"/>
                    <measurement group_id="O5" value="31840" spread="34.55" lower_limit="3.50" upper_limit="6.97"/>
                    <measurement group_id="O6" value="42080" spread="27.83" lower_limit="3.89" upper_limit="7.02"/>
                    <measurement group_id="O7" value="41290" spread="14.63" lower_limit="3.49" upper_limit="6.16"/>
                    <measurement group_id="O8" value="57500" spread="37.51" lower_limit="4.64" upper_limit="8.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Slope</param_type>
            <param_value>0.917</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.0364</dispersion_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.856</ci_lower_limit>
            <ci_upper_limit>0.978</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Secondary Outcome: Relative Change From Baseline of AUC0-4h for Plasma Glucose to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
        <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of plasma glucose. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT plasma glucose total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
        <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
        <population>The pharmacodynamics (PD) analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O9">
            <title>Prednisolone - 60 mg</title>
            <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
          </group>
          <group group_id="O10">
            <title>Pooled Placebo</title>
            <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
          </group>
        </group_list>
        <measure>
          <title>Secondary Outcome: Relative Change From Baseline of AUC0-4h for Plasma Glucose to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
          <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of plasma glucose. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT plasma glucose total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
          <population>The pharmacodynamics (PD) analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
          <units>min*mmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.04" lower_limit="0.963" upper_limit="1.12"/>
                    <measurement group_id="O2" value="1.01" lower_limit="0.932" upper_limit="1.09"/>
                    <measurement group_id="O3" value="1.07" lower_limit="0.990" upper_limit="1.15"/>
                    <measurement group_id="O4" value="1.06" lower_limit="0.986" upper_limit="1.14"/>
                    <measurement group_id="O5" value="1.08" lower_limit="0.999" upper_limit="1.16"/>
                    <measurement group_id="O6" value="1.17" lower_limit="1.09" upper_limit="1.26"/>
                    <measurement group_id="O7" value="1.16" lower_limit="1.08" upper_limit="1.25"/>
                    <measurement group_id="O8" value="1.20" lower_limit="1.12" upper_limit="1.30"/>
                    <measurement group_id="O9" value="1.19" lower_limit="1.11" upper_limit="1.29"/>
                    <measurement group_id="O10" value="1.01" lower_limit="0.964" upper_limit="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.960</ci_lower_limit>
            <ci_upper_limit>1.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.929</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.987</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.983</ci_lower_limit>
            <ci_upper_limit>1.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.995</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.09</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.07</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.11</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline of AUC0-4h for Serum Insulin to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
        <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum insulin. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum insulin total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
        <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
        <population>The PD analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O9">
            <title>Prednisolone - 60 mg</title>
            <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
          </group>
          <group group_id="O10">
            <title>Pooled Placebo</title>
            <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline of AUC0-4h for Serum Insulin to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
          <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum insulin. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum insulin total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
          <population>The PD analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
          <units>min*pmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.19" lower_limit="0.987" upper_limit="1.45"/>
                    <measurement group_id="O2" value="1.20" lower_limit="0.990" upper_limit="1.45"/>
                    <measurement group_id="O3" value="1.03" lower_limit="0.838" upper_limit="1.28"/>
                    <measurement group_id="O4" value="1.04" lower_limit="0.863" upper_limit="1.26"/>
                    <measurement group_id="O5" value="0.999" lower_limit="0.824" upper_limit="1.21"/>
                    <measurement group_id="O6" value="0.980" lower_limit="0.811" upper_limit="1.18"/>
                    <measurement group_id="O7" value="1.15" lower_limit="0.953" upper_limit="1.39"/>
                    <measurement group_id="O8" value="1.16" lower_limit="0.958" upper_limit="1.40"/>
                    <measurement group_id="O9" value="0.784" lower_limit="0.648" upper_limit="0.947"/>
                    <measurement group_id="O10" value="1.14" lower_limit="1.02" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.872</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.874</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.907</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.914</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.762</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.876</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.728</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.860</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.716</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.842</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.687</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.572</ci_lower_limit>
            <ci_upper_limit>0.825</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Change From Baseline of AUC0-4h for Serum C-peptide to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
        <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum C-peptide. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum C-peptide total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
        <time_frame>At Day -1 (baseline) and Day 1 (pre glucose intake and at 30, 60, 90, 120, 150, 180 and 240 minutes post glucose intake)</time_frame>
        <population>The PD analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9567 - 2 mg</title>
            <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O2">
            <title>AZD9567 - 10 mg</title>
            <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O3">
            <title>AZD9567 - 20 mg</title>
            <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O4">
            <title>AZD9567 - 40 mg</title>
            <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O5">
            <title>AZD9567 - 80 mg</title>
            <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O6">
            <title>AZD9567 - 100 mg</title>
            <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O7">
            <title>AZD9567 - 125 mg</title>
            <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O8">
            <title>AZD9567 - 155 mg</title>
            <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
          </group>
          <group group_id="O9">
            <title>Prednisolone - 60 mg</title>
            <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
          </group>
          <group group_id="O10">
            <title>Pooled Placebo</title>
            <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change From Baseline of AUC0-4h for Serum C-peptide to Assess the Effects on Glucose Homeostasis (Oral Glucose Tolerance Test [OGTT])</title>
          <description>To assess the effect of AZD9567 and prednisolone on OGTT after administration of 75 g glucose solution, blood samples were collected pre glucose intake and at post glucose intake for the analyses of serum C-peptide. AUC0-4h relative change between Day 1 and Day -1 was calculated for each subject in a specific treatment group.
Note: Total AUC0-4h was calculated using the linear trapezoidal method. Statistical analysis for the change in OGTT serum C-peptide total AUC0-4h values were assessed via an analysis of variance (ANCOVA), with treatment as fixed effect.</description>
          <population>The PD analysis set consisted of all participants who received a dose of AZD9567/placebo and who had at least one pre-dose and one post-dose measurement for one of plasma glucose, insulin and C-peptide, and who had no major protocol deviations thought to have impacted the analysis of the PD data.</population>
          <units>min*nmol/L</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
                <count group_id="O10" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" lower_limit="0.929" upper_limit="1.22"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.913" upper_limit="1.19"/>
                    <measurement group_id="O3" value="1.02" lower_limit="0.895" upper_limit="1.17"/>
                    <measurement group_id="O4" value="0.933" lower_limit="0.816" upper_limit="1.07"/>
                    <measurement group_id="O5" value="0.919" lower_limit="0.804" upper_limit="1.05"/>
                    <measurement group_id="O6" value="1.00" lower_limit="0.879" upper_limit="1.15"/>
                    <measurement group_id="O7" value="0.983" lower_limit="0.861" upper_limit="1.12"/>
                    <measurement group_id="O8" value="0.968" lower_limit="0.846" upper_limit="1.11"/>
                    <measurement group_id="O9" value="0.749" lower_limit="0.655" upper_limit="0.856"/>
                    <measurement group_id="O10" value="1.08" lower_limit="1.00" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.982</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.861</ci_lower_limit>
            <ci_upper_limit>1.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.961</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.846</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.942</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.829</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.861</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.757</ci_lower_limit>
            <ci_upper_limit>0.979</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.848</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.745</ci_lower_limit>
            <ci_upper_limit>0.964</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.927</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.815</ci_lower_limit>
            <ci_upper_limit>1.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.907</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.798</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.893</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.784</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Ratio (Active Vs Placebo)</param_type>
            <param_value>0.691</param_value>
            <ci_percent>90</ci_percent>
            <ci_lower_limit>0.608</ci_lower_limit>
            <ci_upper_limit>0.785</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>At screening, Day -2, Day -1, Day 1 (at pre-dose; 3 &amp; 12 hours post-dose), Day 2 (24 hours post-dose), Day 3 and follow-up (7 to 10 days after dose)</time_frame>
      <desc>Standard adverse event collection. An adverse event is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD9567 - 2 mg</title>
          <description>In Cohort 1, participants received single dose of AZD8567 2 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E2">
          <title>AZD9567 - 10 mg</title>
          <description>In Cohort 2, participants received single dose of AZD8567 10 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E3">
          <title>AZD9567 - 20 mg</title>
          <description>In Cohort 3, participants received single dose of AZD8567 20 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E4">
          <title>AZD9567 - 40 mg</title>
          <description>In Cohort 4, participants received single dose of AZD8567 40 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E5">
          <title>AZD9567 - 80 mg</title>
          <description>In Cohort 5, participants received single dose of AZD8567 80 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E6">
          <title>AZD9567 - 100 mg</title>
          <description>In Cohort 6, participants received single dose of AZD8567 100 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E7">
          <title>AZD9567 - 125 mg</title>
          <description>In Cohort 7, participants received single dose of AZD8567 125 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E8">
          <title>AZD9567 - 155 mg</title>
          <description>In Cohort 8, participants received single dose of AZD8567 155 mg oral suspension in the fasted state</description>
        </group>
        <group group_id="E9">
          <title>Prednisolone - 60 mg</title>
          <description>In Cohort 9, participants received orally single dose of prednisolone 60 mg capsule in the fasted state</description>
        </group>
        <group group_id="E10">
          <title>Pooled Placebo</title>
          <description>In Cohort 1-8, participants were randomized to AZD9567:placebo (6:2). In Cohort 9, participants were randomized to prednisolone:placebo (6:2)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA version 18.1.</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vessel puncture site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All clinical study findings and documents will be regarded as confidential. The investigator and members of his/her research team must not disclose such information without prior written approval from the sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Clinical Leader</name_or_title>
      <organization>AstraZeneca AB</organization>
      <phone>+46 766 346712</phone>
      <email>clinicaltrialtransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

